News Sentiment

ZVRA sentiment intelligence

Zevra Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.77 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-4.3% over one week, -1.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend active -1.0% over four weeks
Fair value 64.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 40
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 10
Stock Titan 7
simplywall.st 5
GlobeNewswire 4
Finviz 3
www.marketscreener.com 3
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 21
Balance sheet 3
Analyst action 3
Regulatory and legal 2
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
The Manila Times Direct company coverage

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Zevra Therapeutics announced it will report its second-quarter 2026 corporate and financial results on Wednesday, August 5, 2026, via a news release after market close. The company will also host a conference call and audio webcast at 4:30 p.m. ET on the same day. Details for acc

Tone
Neutral 50/100
Event
Earnings
Published
22 Jul 2026 11:40
Source
The Manila Times
Stock Titan Direct company coverage

Zevra’s Aug. 5 results webcast will be replayed for 90 days

Zevra Therapeutics (NasdaqGS: ZVRA) announced it will release its Q2 2026 corporate and financial results on Wednesday, August 5, 2026, after market close, followed by a conference call and audio webcast at 4:30 p.m. ET. A replay of the webcast will be available for 90 days on th

Tone
Neutral 50/100
Event
Earnings
Published
22 Jul 2026 11:40
Source
Stock Titan
Quiver Quantitative Direct company coverage

Zevra Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call

Zevra Therapeutics announced it will release its second quarter 2026 corporate and financial results on August 5, 2026, followed by a conference call and audio webcast at 4:30 p.m. ET. The company, which focuses on developing therapies for rare diseases, highlighted its commitmen

Tone
Neutral 50/100
Event
Earnings
Published
22 Jul 2026 11:40
Source
Quiver Quantitative
Simply Wall Street Direct company coverage

ZVRA - Zevra Therapeutics: Galloping Through a Green Safari

Zevra Therapeutics has successfully transitioned from a prodrug company to a rare disease powerhouse, marked by the FDA approval of MIPLYFFA for Niemann-Pick disease Type C and a $100 million sale of a Rare Pediatric Disease Priority Review Voucher. The company's financial standi

Tone
Positive 75/100
Event
Regulatory and legal
Published
20 Jul 2026 15:11
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

(ZVRA) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting conflicting sentiment across different time horizons and suggesting potential choppy conditions. It presents three institutional trading strategies—Position Trading, Momentum Break

Tone
Neutral 50/100
Event
Balance sheet
Published
13 Jul 2026 01:40
Source
Stock Traders Daily
Sahm Direct company coverage

Is Zevra’s Broad Russell Index Inclusion Reshaping the Investment Case for Zevra Therapeutics (ZVRA)?

Zevra Therapeutics (ZVRA) has been added to several Russell indexes, including the Russell 2000 Value, increasing its visibility among institutional investors. While this inclusion may boost liquidity and trading support, it doesn't alter the fundamental product or regulatory ris

Tone
Positive 65/100
Event
Regulatory and legal
Published
11 Jul 2026 00:09
Source
Sahm
Quartr Direct company coverage

Zevra Therapeutics (ZVRA) Q4 2024 earnings summary

Zevra Therapeutics (ZVRA) reported its Q4 2024 earnings, highlighting its transition to a commercial-stage company with the FDA approval and launch of Miplyffa for Niemann-Pick disease type C. The company achieved $23.6M in net revenue for FY 2024, driven by Miplyffa and OLPRUVA

Tone
Positive 73/100
Event
Earnings
Published
10 Jul 2026 12:12
Source
Quartr
Quartr Direct company coverage

Zevra Therapeutics (ZVRA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Zevra Therapeutics (ZVRA) presented at the Guggenheim Securities Inaugural Healthcare Innovation Conference, highlighting its rare disease focus, two marketed products (MIPLYFFA and OLPRUVA), and late-stage development programs. The company discussed its commercial launch strateg

Tone
Positive 77/100
Event
Market update
Published
08 Jul 2026 23:09
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 144 ZEVRA THERAPEUTICS For: 8 July By Investing.com

This article from Investing.com reports on a Form 144 filing for ZEVRA THERAPEUTICS on July 8. Form 144 filings indicate an intent to sell restricted securities. The brief notice provides no further details beyond the company and date.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:34
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] ZEVRA THERAPEUTICS, INC. SEC Filing

This SEC filing (Form 144) for ZEVRA THERAPEUTICS, INC. details a proposed sale of 10,516 common shares with an aggregate market value of $156,162.60 by an executive. The shares were acquired on July 8, 2026, through a stock option exercise, with payment made in cash. The filing

Tone
Neutral 50/100
Event
Balance sheet
Published
08 Jul 2026 20:09
Source
Stock Titan
Sahm Direct company coverage

Is Zevra Therapeutics (ZVRA) Blending Niche Rare-Disease Focus With Mainstream Index Visibility Effectively?

Zevra Therapeutics (ZVRA) was recently added to several Russell indices, increasing its visibility to institutional investors. This comes as the company also published new clinical data for its Niemann-Pick disease type C therapy, MIPLYFFA, in pediatric patients. The article sugg

Tone
Positive 67/100
Event
Market update
Published
03 Jul 2026 09:40
Source
Sahm
Stock Traders Daily Direct company coverage

(ZVRA) Risk Channels and Responsive Allocation

The article provides an AI-generated analysis of Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting strong near and mid-term sentiment that could extend long-term, with no clear price positioning signal or resistance levels above the current price. It offers three distinct inst

Tone
Positive 75/100
Event
Market update
Published
02 Jul 2026 00:11
Source
Stock Traders Daily
Finviz Direct company coverage

ZVRA - Zevra Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings information for Zevra Therapeutics Inc. (ZVRA), including its last closing price, market capitalization, key financial ratios, stock performance metrics, and analyst recommendations. It presents a comprehensive overview of the company'

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 12:10
Source
Finviz
TradingView Direct company coverage

Enterprise value to revenue forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA

This article is a financial data page from TradingView focusing on Zevra Therapeutics, Inc. (NASDAQ: ZVRA). It provides an overview of the company's financial data, specifically its enterprise value to revenue forward metric. The page includes general market information and links

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 07:39
Source
TradingView
Finviz Direct company coverage

ZVRA - Zevra Therapeutics Inc Dividends

This article provides detailed financial and stock performance data for Zevra Therapeutics Inc (ZVRA). It lists key metrics such as market capitalization, income, sales, price-to-earnings ratio, various growth rates, and insider/institutional ownership percentages. The data indic

Tone
Neutral 50/100
Event
Macro sensitivity
Published
29 Jun 2026 19:39
Source
Finviz
www.marketscreener.com Direct company coverage

Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell 2000 Value Benchmark

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell 2000 Value Benchmark, indicating its inclusion in this significant index. This update highlights the company's growing presence in the financial markets and follows other recent inclusions in related Russell i

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 11:08
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to Russell Microcap Value Benchmark Index

Zevra Therapeutics, Inc. (NasdaqGS:ZVRA) has been added to the Russell Microcap Value Benchmark Index. This inclusion is part of a series of recent additions to various Russell indexes, including the Russell 2000 Value Benchmark and Russell 3000 Value Benchmark. The company is a

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 09:26
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 3000E Value Benchmark

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 3000E Value Benchmark, effective June 28, 2026. The company, a commercial-stage rare disease firm, also saw its shares added to several other Russell indices, including the Russell 2000 Value and Microcap Val

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 08:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Zevra Therapeutics, Inc.(NasdaqGS: ZVRA) added to Russell 2000 Value-Defensive Index

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has been added to the Russell 2000 Value-Defensive Index. This announcement highlights the company's progress and recognition within the financial markets. Zevra Therapeutics is a commercial-stage rare disease company focusing on developi

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 03:10
Source
www.marketscreener.com
TradingView Direct company coverage

Price to book forward of Zevra Therapeutics, Inc. – DUS:1GDA

This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating no trades a

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 22:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Zevra Therapeutics, Inc. – NASDAQ:ZVRA

This article provides financial information for Zevra Therapeutics, Inc. (NASDAQ: ZVRA), specifically focusing on its price to sales forward metric. The content highlights the company's financial overview within the pharmaceuticals sector, as presented on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Zevra Therapeutics, Inc. – DUS:1GDA

This article provides financial information for Zevra Therapeutics, Inc. (DUS:1GDA), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's financial data on the Dusseldorf Stock Exchange as presented on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:09
Source
TradingView
TradingView Direct company coverage

Zevra Therapeutics, Inc. Actuals & Estimates (SWB:1GDA)

This article provides financial actuals and estimates for Zevra Therapeutics, Inc. (SWB:1GDA), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's past earnings performance, revenue figures, and upcoming earnings re

Tone
Positive 65/100
Event
Earnings
Published
27 Jun 2026 07:09
Source
TradingView
TradingView Direct company coverage

Zevra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:1GDA)

This article provides an overview of Zevra Therapeutics, Inc. (TRADEGATE:1GDA) stock, including financial actuals, analyst estimates, and key performance indicators. It covers projected price targets, historical stock prices, upcoming earnings dates, recent earnings and revenue f

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Zevra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ZVRA)

This article provides an overview of Zevra Therapeutics, Inc. (ZVRA) stock performance, financials, and analyst forecasts. It covers recent price changes, historical highs and lows, market capitalization, upcoming earnings reports, and revenue details, along with analyst predicti

Tone
Positive 70/100
Event
Earnings
Published
25 Jun 2026 23:40
Source
TradingView
TradingView Direct company coverage

1GDA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Zevra Therapeutics, Inc. (1GDA) stock, including analyst price targets, historical highs and lows, and upcoming earnings information. Analysts have given a max estimate of 30.34 EUR and a min estimate of 18.20 EUR for the stock's future price.

Tone
Positive 63/100
Event
Analyst action
Published
25 Jun 2026 17:40
Source
TradingView